Margaret Liu - Ipsen SA Independent Director
| IPN Stock | EUR 106.30 0.10 0.09% |
Director
Dr. Margaret A. Liu, M.D. serves as Independent Director of Ipsen SA June 7, 2017. She is currently a consultant in the fields of health, vaccines and Immunotherapy, for pharmaceutical biotechnology companies, companies institutions, universities, and government scientific research committees. She is Professor at the Karolinska Institute in Stockholm, Sweden since 2003, first as as Visiting Professor, then currently as Foreign Adjunct Professor . She is also Adjunct Full Professor at the University of California at San Francisco since 2013 and President of the International Society for Vaccines since 2016. She previously held various positions in the private and public sectors in parallel with her academic career. From 1984 to 1988, she was Visiting Scientist at Massachussetts Institute of Technology. From 1987 to 1989 she was Instructor of Medicine at Harvard University. From 1989 to 1995, she was Adjunct Assistant Professor of Medicine at the University of Pennsylvania at Philadpelphie. From 1990 at 1997, she was Director, then Senior Director of the Viral and Cell Biology Division at the Laboratories Merck. From 1997 to 2000, she was VicePresident of Research for the Vaccines and VicePresident of the Vaccines and Gene Therapy division of Chiron Corporation in Emeryville, California. From 2000 to 2002, she was Senior Advisor in Vaccinology for the Bill Melinda Gates Foundation. From 2000 to 2006, she was Vice President of the Board of Transgene in Strasbourg, France. From 2005 to 2009, she was Director of Sangamo Biosciences Inc. She is a recognized scientist in the field of research and development in vaccines and vaccination programs against infectious diseases, in particular HIV and in the field of gene therapies. She holds a B.Sc. in Chemistry with honors from Colorado College and a Ph.D. from Harvard Mediccal School. since 2017.
| Age | 63 |
| Tenure | 7 years |
| Phone | 33 1 58 33 50 00 |
| Web | https://www.ipsen.com |
Ipsen SA Management Efficiency
The company has return on total asset (ROA) of 0.1026 % which means that it generated a profit of $0.1026 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1944 %, meaning that it generated $0.1944 on every $100 dollars invested by stockholders. Ipsen SA's management efficiency ratios could be used to measure how well Ipsen SA manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Thierry Morin | Arkema SA | 66 | |
| Philippe Vassor | Arkema SA | 63 | |
| Nathalie Muracciole | Arkema SA | 53 | |
| Victoire Margerie | Arkema SA | 55 | |
| Claire Pedini | Arkema SA | 50 | |
| Marc Pandraud | Arkema SA | 59 | |
| JeanMarc Bertrand | Arkema SA | N/A | |
| Yannick Assouad | Arkema SA | 59 | |
| Francois Enaud | Arkema SA | 58 | |
| MarieJose Donsion | Arkema SA | 46 | |
| Isabelle BocconGibod | Arkema SA | 50 | |
| Laurent Mignon | Arkema SA | 54 | |
| MarieAnge Debon | Arkema SA | 52 | |
| Helene MoreauLeroy | Arkema SA | 54 | |
| Patrice Breant | Arkema SA | 62 | |
| Bernard Kasriel | Arkema SA | 70 | |
| Alexandre Juniac | Arkema SA | 54 | |
Management Performance
Ipsen SA Leadership Team
Elected by the shareholders, the Ipsen SA's board of directors comprises two types of representatives: Ipsen SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ipsen. The board's role is to monitor Ipsen SA's management team and ensure that shareholders' interests are well served. Ipsen SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ipsen SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Herve Couffin, Independent Director | ||
| Helene AuriolPotier, Director | ||
| Carol Xueref, Independent Director | ||
| Richard Paulson, Executive Vice President and Chief Executive Officer of Ipsen North America | ||
| Yan Moore, Senior Vice President Head of Oncology Therapeutics Area | ||
| James Levine, President | ||
| Margaret Liu, Independent Director | ||
| Claude Bertrand, Chief Scientific Officer and Executive VP of RandD | ||
| Stephane Bessette, Executive Vice President of Human Resources | ||
| Christel Bories, Deputy CEO | ||
| Howard Mayer, Executive Vice President, Head of Research & Development | ||
| Christophe Verot, Director | ||
| Regis Mulot, Chief Human Resource Officer, Executive Vice President | ||
| Jean Fabre, Executive Vice President - Primary Care Business Unit, Member of the Executive Committee | ||
| David Meek, Chief Executive Officer, Director | ||
| Alexander McEwan, Vice President and Head of Radiopharmaceuticals | ||
| Etienne Blois, Vice President Latin America, Spain and Portugal | ||
| Ivana MagovcevicLiebisch, Executive Vice President Chief Business Officer | ||
| Philippe Bonhomme, Director, Permanent representative of Beech Tree SA | ||
| Heather White, Vice President Global Internal Audit | ||
| Martha Crawford, Independent Director | ||
| Harout Semerjian, Executive Vice President & President Specialty Care International & Global Franchises | ||
| Anne Beaufour, Director, Permanent representative of Highrock S.àr.l. | ||
| Christopher Masterson, Senior Vice President Quality | ||
| Benoit Hennion, Executive Vice President and President Consumer Helathcare | ||
| Antoine Flochel, Vice Chairman of the Board | ||
| Marc Garidel, Chairman, CEO and Chairman of Strategic Committee | ||
| Paul Sekhri, Independent Director | ||
| Henri Beaufour, Director | ||
| Gwenan White, Executive Vice President Communications and Public Affairs | ||
| Francois Garnier, Executive Vice President General Counsel, Member of the Executive Committee | ||
| Ivana Magovcevic, Executive Vice President Chief Business Officer | ||
| Dominique Bery, Executive Vice President, Strategy and Transformation | ||
| Alexandre LeBeaut, Executive Vice President Research & Development, Chief Scientific Officer | ||
| Pierre Boulud, Executive Vice President - Specialty Care Commercial Operations, Member of the Executive Committee | ||
| Aidan Murphy, Executive Vice-President Technical Operations | ||
| Piet Wigerinck, Independent Director | ||
| David Loew, Chief Executive Officer, Director | ||
| Craig Marks, VicePres Relations | ||
| Pierre Martinet, Independent Director | ||
| Yan MD, VP Area | ||
| Jonathan Barnsley, Executive Vice-President Technical Operations, Member of the Executive Committee | ||
| Dominique Brard, Executive Vice President - Human Resources and Member of the Executive Committee | ||
| FrancoisMaurice Garnier, Executive Vice President General Counsel | ||
| Cynthia Schwalm, the United States General Manager | ||
| Philippe RobertGorsse, Executive Vice President - Specialty Care Franchises, Member of the Executive Committee | ||
| Michele Ollier, Independent Director | ||
| Carol Stuckley, Independent Director | ||
| JeanMarc Parant, Director, representing Employees | ||
| Steven Hildemann, Executive Vice President Chief Medical Officer, Head of Global Medical Affairs and Pharmacovigilance | ||
| Christophe Jean, Executive Vice President - Group Strategy and Business Development, Member of the Executive Committee | ||
| Philippe LopesFernandes, Executive Vice President Chief Business Officer | ||
| Aymeric Chatelier, Interim Chief Executive Officer, Chief Financial Officer, Executive Vice President | ||
| Didier Veron, Senior Vice President Public Affairs and Corporate Communication | ||
| Eugenia Litz, Vice President of Investor Relations | ||
| Dominique Laymand, Executive Vice President, Chief Ethics and Compliance Officer | ||
| Stephan Gagne, Head Office |
Ipsen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ipsen SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.19 | |||
| Return On Asset | 0.1 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 0.28 % | |||
| Current Valuation | 8.46 B | |||
| Shares Outstanding | 82.63 M | |||
| Shares Owned By Insiders | 57.12 % | |||
| Shares Owned By Institutions | 20.19 % | |||
| Price To Earning | 13.13 X | |||
| Price To Book | 2.88 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ipsen SA. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Complementary Tools for Ipsen Stock analysis
When running Ipsen SA's price analysis, check to measure Ipsen SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ipsen SA is operating at the current time. Most of Ipsen SA's value examination focuses on studying past and present price action to predict the probability of Ipsen SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ipsen SA's price. Additionally, you may evaluate how the addition of Ipsen SA to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |